Results 111 to 120 of about 26,612 (257)

Linagliptin: from bench to bedside

Drug Design, Development and Therapy, 2014
John DoupisIatriko Palaiou Falirou Medical Center, Division of Diabetes, Athens, GreecePurpose: The nature of biomedical research affords a broad range of investigational topics at the preclinical stage, not all of which may be explored in subsequent ...
Doupis J
doaj  

Association of Lipid Ratios With Cardiovascular Outcomes in Type 2 Diabetes: A Population Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro, Jose Antonio Quesada, Manuel A. Ruiz‐Quintero, Didac Mauricio, Kamlesh Khunti, Domingo Orozco‐Beltrán   +5 more
wiley   +1 more source

A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition

Терапевтический архив, 2013
AIM: To study the impact of intensified therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor vilagliptin or sulfonylurea (SU) on the control of glycemia, weight, and quantitative body composition in patients with type 2 diabetes mellitus (DM-2) who ...
M V Shestakova, O Iu Sukhareva, T O Chernova, I A Shmushkovich, A A Aleksandrov, A V Il'in, I I Dedov   +6 more
doaj  

Thalidomide and a Dipeptidyl Peptidase 4 Inhibitor in a Rat Model of Experimental Autoimmune Myocarditis. [PDF]

Korean Circ J, 2023
Kim KJ, Park JB, Lee SP, Kim HK, Kim YJ.
europepmc   +1 more source

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment

Diabetes, Metabolic Syndrome and Obesity, 2013
David ScottClinical Research Development Associates, Rosedale, NY, USAAbstract: Diabetes is the leading cause of chronic kidney disease, and the prevalence of both diseases is rising worldwide.
Scott D
doaj  

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires, Matheus Menezes‐Santos, Andréa Costa Goes, Heitor Siqueira Ribeiro, Luana Ferreira Alves, Beatriz Cruz dos Santos, Jéssyca Teles Barreto, Roberta Cristina Vieira Meneses, Ana Mara de Oliveira e Silva, Ana Hermínia Andrade e Silva, Sadraque Eneas de Figueiredo Lucena   +10 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid in an Elderly Woman With Type 2 Diabetes Mellitus: A Case Report. [PDF]

Cureus
Roa Alvarez G, Shuchleib Cukiert M, Hernández Altamirano FR, Berumen Glinz C, Vega Memije ME.   +4 more
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitor

Journal of the American College of Cardiology, 2012
openaire   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source